Brian Nowosielski

With a 7-year target date, the FDA is moving away from 10-digit NDCs and toward a universal 12-digit format.

In a recent research letter, investigators establish how removal of in-person dispensing requirements impact mifepristone pharmacy access.

In this episode, Natalie DiPietro Mager, PharmD, PhD, meets with Kami Dixon, MD, MA, to discuss the racial disparities across women’s health in the US.

Exploring both patient-level and organizational factors, researchers assess community pharmacy accessibility for immunizations and injectables.

In part 2, Neal Cooper and Matt Sample address the foreseeable challenges and necessary questions surrounding the FDA’s push toward 12-digit national drug codes.

Chad Worz, PharmD, BCGP, FASCP, and Jeffrey Hogan, present on the implications behind major PBM reform signed in February and how the reimbursement landscape is expected to shift.

Matt Sample and Neal Cooper join to discuss the beginning stages of the FDA’s 7-year rollout of new NDCs for prescription drugs.

This episode explores the gaps between pharmacy leaders and the communities, and patients, that they serve.

Researchers assess medication adherence across initial combination therapy users during their first year of type 2 diabetes treatment.

With persistent challenges in the arena of US maternal health care, researchers assess pharmacists’ knowledge, confidence, and perceived barriers in filling maternal health gaps.

Pharmacists expand vaccine access, but billing rules, payer barriers, and uneven reimbursement keep immunization services from scaling nationwide.

With workforce and work-life balance issues plaguing pharmacy, the newly introduced hybrid pharmacist role is creating innovation across the greater pharmacy industry.

Episode 9 dives into the landscape of obesity pharmacotherapy, detailing current therapies, clinical updates, future pipelines, and more.

As debates heat up between anti-abortion and pro-life advocates, the federal government places a hold on any action toward mifepristone’s approval.

In part 2 of our interview with Walgreens Chief Pharmacy Officer Rick Gates, he explored the modernization behind his organization’s newly introduced ‘hybrid pharmacist’ role.

In response to evolving serotypes and vaccine guidance, researchers assess the most effective pneumococcal vaccination strategies across Taiwan.

Researchers aim to update and expand on register-based surveillance of severe acute respiratory infections related to Streptococcus pneumoniae in Denmark.

Emily Eddy, PharmD, BCACP, BC-ADM, CDCES, presents on the ever-expanding world of glucagon-like peptide-1s, now heading toward indications for chronic kidney disease and substance use disorder.

Rick Gates, chief pharmacy officer at Walgreens, helps introduce his organization’s innovative new ‘hybrid pharmacist’ role.

Benjamin Jolley, PharmD, presents on recent developments regarding pharmacy benefit manager reform on the state and federal levels.

With a slew of new GLP-1 indications approved in recent history, researchers and experts are now diving into their use in treating substance use disorders.

Travis Wolff, PharmD, BCACP, presents on the current landscape of medical billing in pharmacy practice and the steps pharmacists can take to realize a significantly higher profit margin.

In part 2, Sylvie Stacy, MD, MPH, explores the current evidence regarding GLP-1s for SUD, the work still necessary in the future of this space, and where pharmacists fall within it all.

Jon Grice, PharmD, MSA, vice president of pharmacy insights at Outcomes, explores the framework necessary and steps businesses must take to ensure pharmacy growth.

Event moderator Jesse McCullough, PharmD, wraps up the Total Pharmacy Solutions Summit Spring 2026 event with key takeaways and insights into the evolving road pharmacy is headed on.

Blair Thielemier, PharmD, EQUIPP customer success manager at PQS by Innovaccer, offers insight into key technology being used to realize greater revenue for pharmacy businesses.

Ketan Mehta, CEO and president of PrimeRx, presented a keynote session on helping independent pharmacies diversify purchasing, improve cash flow, and reduce the cost of goods sold.

In this episode, host Taylor Watterson, PharmD, PhD, welcomes Emily Hoffins, MS, PhD, postdoctoral researcher in the SCRPTS Lab at the University of Illinois Chicago Retzky College of Pharmacy.

Suzanne K. Higginbotham, PharmD, BCACP, CTTS, CDCES, further discusses her APhA 2026 presentation titled “Real-Time. Real Change. Rethinking CGM for Today's Patient.”

Sylvie Stacy, MD, MPH, introduces her work on GLP-1s for addiction and the new pathways this drug class can introduce for patients living with SUD.